Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (April 2010)

25 slides from Paratek Pharmaceuticals's investor presentation, Apr 27, 2010

  1. Slide 1: April 2010

    April 2010 April 2010 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in psychiatry and neuroscience Exhibit 99.1

  2. Slide 2: Forward looking statements

    Forward looking statements Forward looking statements This slide deck contains forward-looking statements that are based upon current expectations within the meaning of the Private Securities Reform Act of 1995 and for which we intend that protection be gained by the safe harbor created thereby. Suc

  3. Slide 3: Transcept Pharmaceuticals: company profile

    Transcept Pharmaceuticals: company profile Transcept Pharmaceuticals: company profile Public listing through reverse merger in Jan 2009 – Nasdaq:TSPT (zolpidem tartrate sublingual tablet): lead product candidate U.S. primary care partnership with Purdue Pharma, psychiatry co-promote option Strong ba

  4. Slide 4: Transcept Pharmaceuticals: key corporate events

    Transcept Pharmaceuticals: key corporate events Transcept Pharmaceuticals: key corporate events : Preclinical program and two Phase 3 studies completed: 2004-2008 NDA submitted: September 2008 U.S. commercial partnership: Purdue, primary care marketing and sales: July 2009 Complete Response Letter r

  5. Slide 5: Intermezzo

    Intermezzo ® Proposed indication statement: Intermezzo (zolpidem tartrate sublingual tablet) is indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep

  6. Slide 6: Total Annual Prescriptions (MAT millions)

    Total Annual Prescriptions (MAT millions) U.S. insomnia market: ~76 M insomnia Rxs and ~5% Rx growth in the recent month period U.S. insomnia market: ~76 M insomnia Rxs and ~5% Rx growth in the recent month period (1) For the 12-month period ended March 2010. Source Wolters Kluwer Pharma Solutions.

  7. Slide 7: Stanford Sleep Epidemiology Research Center: middle of the night awakening: #1 insomnia symptom

    Stanford Sleep Epidemiology Research Center: middle of the night awakening: #1 insomnia symptom Stanford Sleep Epidemiology Research Center: middle of the night awakening: #1 insomnia symptom Large scale population based sleep epidemiology study , ~9,000 subjects over 4 years 35% report awakenings a

  8. Slide 8: No product currently indicated for prn treatment of middle of the night awakening

    : No product currently indicated for prn treatment of middle of the night awakening Middle of the night awakenings typically did not occur every night, even in a more severely affected patient group Commonly prescribed 7 to 8 hour sleep aids require bedtime prophylactic dosing before an awakening oc

  9. Slide 9: Sleep lab clinical result: minute sleep onset with 3.5 mg dose

    Sleep lab clinical result: 14 minute sleep onset with 3.5 mg dose In two Phase 3 studies, no significant next day residual effects as compared to placebo Sublingual tablet dissolves in ~ 2 minutes pH drives zolpidem base, rapidly absorbed 72% lower dose than Ambien CR , the most commonly prescribed

  10. Slide 10: 3.5 mg delivered greater early zolpidem bioavailability than ~3x higher Ambien dose

    3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien dose 3.5 mg delivered greater early zolpidem bioavailability than a ~3x higher Ambien dose PK comparison study: Intermezzo 3.5mg vs. Ambien 10mg PO n=33 Time (min) 9.3x 2.9x 1.4x 3.5 mg Ambien 10 mg

  11. Slide 11: Regulatory Review

    Regulatory Review Regulatory Review

  12. Slide 12: FDA Complete Response Letter: October 2009

    FDA Complete Response Letter: October 2009 FDA Complete Response Letter: October 2009 FDA indicated Transcept has submitted substantial evidence of effectiveness for the use of in its intended indication FDA recognized that the Intermezzo data did not indicate significant next-day residual effects a

  13. Slide 13: NDA resubmission: next steps

    NDA resubmission: next steps NDA resubmission: next steps Inadvertent re-dosing in a single night FDA has indicated that redesigned unit dose packaging appears to reduce the potential for inadvertent re-dosing in a single night Inadvertent dosing with less than four hours FDA has agreed to a pre-app

  14. Slide 14: Highway driving study overview

    Highway driving study overview Highway driving study overview Approximately 40 healthy adult volunteers Highway driving over a one-hour period Single-center (Maastricht), double-blind, randomized, placebo-controlled crossover design Key comparisons: – 3.5mg vs. placebo, 4 hours post-dose – 3.5mg vs.

  15. Slide 15: U.S. Commercial Partnership: Purdue Pharma

    U.S. Commercial Partnership: Purdue Pharma U.S. Commercial Partnership: Purdue Pharma

  16. Slide 16: Purdue Pharma: U.S. primary care marketing partner

    Purdue Pharma: U.S. primary care marketing partner Purdue Pharma: U.S. primary care marketing partner > $2 billion 2008 revenue, leading pain therapeutic franchise, significant U.S. primary care marketing and sales presence : an important new product opportunity for Purdue Purdue team actively engag

  17. Slide 17: Purdue Pharma agreement: key Transcept benefits

    Purdue Pharma agreement: key Transcept benefits Purdue Pharma agreement: key Transcept benefits Purdue to commercialize Intermezzo to U.S. primary care market Milestone payments – Upfront license fee: $25M received August 2009 – Up to $30M additional after Purdue’s acceptance of an NDA approval, red

  18. Slide 18: Financial Overview

    Financial Overview Financial Overview

  19. Slide 19: Financial position: December 31, 2009

    Financial position: December 31, 2009 Financial position: December 31, 2009 Cash & investments: $88.9 M 4Q09 cash burn rate : $1.4 M / month Shares outstanding: 13.4 M Options / warrants / other: 1.9 Total: 15.3 M Employees (3/15/10):

  20. Slide 20: Intermezzo: Intellectual property

    Intermezzo ® : Intellectual property : Intellectual property

  21. Slide 21: Two formulation patents issued; method of use patents pending

    : two formulation patents issued; method of use patents pending : two formulation patents issued; method of use patents pending Formulation for transmucosal absorption – two issued U.S. patents - 7,682,628 and 7,658,945 – patents expire no sooner than February 2025 – low dose zolpidem, ~1mg to ~5mg

  22. Slide 22: Pipeline development

    Pipeline development Pipeline development

  23. Slide 23: TO-2061 treatment resistant obsessive compulsive disorder (OCD)

    TO-2061 – treatment resistant obsessive compulsive disorder (OCD) – ondansetron down-regulates dopamine – low dose ondansetron augmentation of SSRIs – obsessive compulsive disorder pilot trials positive data in OCD resistant to SSRI and atypical antipsychotic therapy further exploratory clinical stu

  24. Slide 24: Key Transcept goals and activities

    Key Transcept goals and activities Key Transcept goals and activities Completed Intermezzo US marketing partnership, July 09 Patent coverage: two Intermezzo formulation patents issued Proposal to FDA on Intermezzo NDA resubmission, Feb 10 FDA agreement on highway driving study design, March 10 Start

  25. Slide 25: Registered trademark notice

    is a registered trademark of Transcept Pharmaceuticals, Inc.

Transcept Pharmaceuticals — Investor Presentation (April 2010) on 6ix